MAPT and Alzheimer disease: Previous studies have demonstrated that CSF p-tau T217 could potentially be a key biomarker to monitor tau pathology in AD pathophysiology, and that its role might differ from other p-tau biomarkers.6,7 In this study, we introduced a novel immunoassay, detecting p-tau T217 in CSF, which is based on the highly sensitive Simoa technology.